ReVision Optics, Inc. (RVO), a leader in implantable presbyopia-correcting corneal inlay technology, announces the appointment of Nick J. Manesis, PhD as Vice President of R&D. Dr. Manesis brings to RVO nearly 30 years of materials research and development experience, including at the leading ophthalmic companies Allergan and CooperVision.
“Nick’s experience is highly relevant to our efforts to continue to advance the Raindrop Near Vision Inlay’s delivery systems as well as materials technology. Of note, his work at CooperVision and Allergan included biomaterials used in the manufacture of hydrogel contact lenses, corneal implants and other ocular lenses,” said John Kilcoyne, ReVision Optics President and Chief Executive Officer. “The R&D function is critical to our leadership and innovation strategy, and we are delighted to have Nick’s extensive knowledge base, technical and analytical expertise to lead us in these efforts.”
The Raindrop Near Vision Inlay, a microscopic hydrogel inlay designed to correct presbyopia, received U.S. Food and Drug Administration (FDA) approval on June 29, 2016 and will be commercially launched in the U.S. in late August 2016. The Raindrop Near Vision Inlay is also approved in the European Union, South Korea, Australia and New Zealand.
“It’s exciting to join the RVO team to assist in the commercialization of this innovative approach to correcting presbyopia and to support the development of future innovative products,” said Dr. Manesis. “I look forward to being a part of the company’s entrepreneurial culture with a strong near and long term focus on the commercial success of the Raindrop.”
Dr. Manesis most recently was Vice President at a specialty materials company Solaris Technology Group, where he was engaged in building out a technology platform for life science applications. Prior to that he served for five years as Vice President, Research and Development at Allergan, where he led and managed U.S. and international R&D teams and had responsibilities for designing and building laboratories, hiring staff and forming systems and procedures. Dr. Manesis previously was Director, Chemistry and Materials Science at CooperVision, where he was instrumental in developing silicone hydrogel contact lens products manufactured on that company’s existing platform and in managing innovation initiatives, materials development, and analytical activities for new and existing lens products. He previously was Director of Business Development at Smart Products, Engineer at Hewlett-Packard Company, and Senior Scientists at Pilkington Barnes Hind (PBH) and Allergan Medical Optics (AMO). Dr. Manesis received BS degrees in Chemistry and Biology from the University of Wisconsin, Eau Claire, and an MS and PhD in chemistry from the University of California, San Diego.
About the Raindrop Near Vision Inlay
The Raindrop Near Vision Inlay is placed in the cornea of the non-dominant eye during a 10-minute procedure. The Raindrop is comprised of approximately 80% water and has a refractive index very similar to the cornea. It is transparent and therefore does not restrict the amount of light reaching the retina. The reshaping of the anterior curvature of the cornea improves near vision.
The Raindrop Near Vision Inlay has received approval by the U.S. Food and Drug Administration, authorization to affix the CE Mark for the European Union, license approval by the Ministry of Food and Drug Safety (South Korea), approval by the Therapeutic Goods Administration (Australia), and registration with the Medicines and Medical Safety Authority (New Zealand). Other country-specific registrations are pending.
About ReVision Optics
ReVision Optics, Inc. focuses on the development and commercialization of innovative optical solutions dedicated to presbyopic vision correction. The company’s Raindrop Near Vision Inlay offers a unique, patented refractive surgery solution. The Raindrop improves near vision that has been lost through the eye’s natural aging process called presbyopia. The Raindrop Near Vision Inlay provides an ideally suited surgical option for near vision enhancement.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160810005189/en/